Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methotrexate + Corticosteroid for Grade III-IV aGVHD
NCT04958538Phase 2Unknown
- Sponsor
- Peking University People's Hospital
- Start
- Apr 2021
- Primary completion
- Dec 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of methotrexate in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Peking University People's Hospital. Primary endpoint: Overall Response Rate at 14 days. Status: unknown.
02
Drugs
methotrexate
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT04958538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04958538.